ABVX Key Statistics, Chart & Performance
The current stock price of ABVX is 128.23 USD. In the past month the price increased by 36.06%. In the past year, price increased by 1403.28%.
ABVX Latest News, Press Relases and Analysis
ABVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About ABVX
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA-ADR
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 67
Phone: 33153830963
ABIVAX SA-ADR / ABVX FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the current price of ABVX stock?
The current stock price of ABVX is 128.23 USD. The price increased by 2% in the last trading session.
Does ABIVAX SA-ADR pay dividends?
ABVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVX stock?
ABVX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ABIVAX SA-ADR belong to?
ABIVAX SA-ADR (ABVX) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for ABVX stock?
ABIVAX SA-ADR (ABVX) currently has 67 employees.
What is ABIVAX SA-ADR worth?
ABIVAX SA-ADR (ABVX) has a market capitalization of 9.98B USD. This makes ABVX a Mid Cap stock.
ABVX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
ABVX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ABVX. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative.
ABVX Financial Highlights
Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS increased by 18.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX Forecast & Estimates
14 analysts have analysed ABVX and the average price target is 123.46 USD. This implies a price decrease of -3.72% is expected in the next year compared to the current price of 128.23.
For the next year, analysts expect an EPS growth of -3.38% and a revenue growth 91.53% for ABVX